Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:deep_vein_thrombosis
|
| gptkbp:activities |
activates antithrombin III
inhibits thrombin |
| gptkbp:appointed_by |
injection
intravenous route subcutaneous route |
| gptkbp:brand |
Lovenox
Arixtra Fragmin |
| gptkbp:contraindication |
active bleeding
severe thrombocytopenia |
| gptkbp:developed_by |
animal tissues
|
| gptkbp:discovered_by |
1916
|
| gptkbp:financial_performance |
sodium bicarbonate
sodium chloride |
| gptkbp:has_impact_on |
platelet function
fibrin formation |
| https://www.w3.org/2000/01/rdf-schema#label |
heparin
|
| gptkbp:influences |
blood coagulation
|
| gptkbp:ingredients |
C12 H19 N2 O20 S5
|
| gptkbp:interacts_with |
gptkb:warfarin
antiplatelet agents NSAI Ds |
| gptkbp:is_available_on |
vials
pre-filled syringes low molecular weight heparin unfractionated heparin |
| gptkbp:is_monitored_by |
anti-Xa levels
a PTT |
| gptkbp:is_part_of |
anticoagulation therapy
critical care medicine periprocedural management |
| gptkbp:is_subject_to |
gptkb:municipality
pharmacovigilance dosage adjustments |
| gptkbp:is_used_for |
preventing blood clots
treating deep vein thrombosis treating pulmonary embolism |
| gptkbp:is_used_in |
gastroenterology patients
neurology patients oncology patients venous thromboembolism treatment myocardial infarction treatment obstetrics patients orthopedic surgery patients thromboprophylaxis |
| gptkbp:produced_by |
mast cells
bovine lung porcine intestinal mucosa |
| gptkbp:regulates |
gptkb:FDA
|
| gptkbp:replaced_by |
dog liver
|
| gptkbp:side_effect |
bleeding
thrombocytopenia |
| gptkbp:suitable_for |
patients with severe renal impairment
patients with severe liver disease patients with active bleeding disorders |
| gptkbp:used_in |
pregnancy
dialysis postoperative care cardiac surgery acute coronary syndrome |
| gptkbp:weight |
6000 to 30000 Da
|